髓源性抑制细胞在癌症中的预后作用：系统评价和荟萃分析。
Prognostic role of myeloid-derived suppressor cells in cancers: a systematic review and meta-analysis.
机构信息
Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Institute of Geriatrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
出版信息
BMC Cancer. 2018 Dec 5;18(1):1220. doi: 10.1186/s12885-018-5086-y.
BACKGROUND
Myeloid-derived suppressor cells (MDSCs) is a heterogeneous population of immature myeloid cells, inhibiting both the innate and adaptive immunity. Recent studies validated that MDSCs caused immune suppression and promoted cancer progression through various mechanisms. However, the prognostic value of MDSCs in cancer remains controversial.
METHODS
Here, we performed this meta-analysis to evaluate the prognostic value of MDSCs in various types of cancer. The electric databases, such as Pubmed, Embase and Web of Science, were searched for relevant publications. Hazards ratios (HRs) with the corresponding 95% confidence intervals (95%CIs) were calculated to evaluate the prognostic role of MDSCs in cancer.
RESULTS
A total of 16 studies with 1864 patients were enrolled in our meta-analysis. Elevated MDSCs frequency was shown to be associated with shorter overall survival (OS) (HR = 2.46, 95%CI: 1.87-3.23), and poor disease-free survival / recurrence-free survival (DFS / RFS) (HR = 3.26, 95%CI: 2.10-5.04) after treatment. Furthermore, similar results were also observed in the stratified subgroup analysis, which included the analysis by region, sample size, cancer type, NOS scores, subtype and cut-off value of MDSCs.
CONCLUSION
High MDSCs might be related to poor clinical outcomes of patients with cancer, that is, MDSCs might be a potential prognostic biomarker in cancer.
背景
髓系来源的抑制细胞（MDSCs）是一种异质性的未成熟髓系细胞群体，抑制固有和适应性免疫。最近的研究证实，MDSCs 通过多种机制引起免疫抑制并促进癌症进展。然而，MDSCs 在癌症中的预后价值仍存在争议。
方法
在这里，我们进行了这项荟萃分析，以评估 MDSCs 在各种类型癌症中的预后价值。检索了 Pubmed、Embase 和 Web of Science 等电子数据库中的相关出版物。使用风险比（HRs）及其相应的 95%置信区间（95%CI）来评估 MDSCs 在癌症中的预后作用。
结果
共有 16 项研究，共纳入 1864 名患者，纳入了我们的荟萃分析。结果表明，MDSCs 频率升高与总生存期（OS）较短（HR=2.46，95%CI：1.87-3.23）和治疗后无病生存/无复发生存（DFS/RFS）较差（HR=3.26，95%CI：2.10-5.04）相关。此外，在分层亚组分析中也观察到了类似的结果，包括按地区、样本量、癌症类型、NOS 评分、亚型和 MDSCs 的截止值进行的分析。
结论
高 MDSCs 可能与癌症患者的临床结局不良相关，即 MDSCs 可能是癌症中一种潜在的预后生物标志物。
Zotero 插件